Latest Analgesics Stories

CHADDS FORD, Pa., June 14, 2012 /PRNewswire/ -- Endo Health Solutions (Nasdaq: ENDP), today announced the completion of the company's transition of its OPANA ER franchise to the new formulation designed to be crush resistant. In connection with the completion of this transition, the U.S. Food and Drug Administration (FDA) has moved the old formulation of OPANA ER to the Orange Book Discontinued List. "While the original formulation of OPANA ER was deemed by FDA to be safe and...

SAN DIEGO, June 13, 2012 /PRNewswire/ -- Millennium Laboratories today applauded the unanimous 12-0 decision of a Federal jury and confirming order by United States District Court Judge Benson Everett Legg finding Ameritox's advertising claims about its Rx Guardian and Rx Guardian CD medication monitoring system to be literally false and material, and "actually deceives or had the tendency to deceive" physicians. The court found that monetary damages would be insufficient to...

French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients. Dr Laurent Varin, an anesthesiologist at the Caen Teaching Hospital (Caen, France), presented the findings to the European Anaesthesiology...

SHELTON, Conn., June 11, 2012 /PRNewswire/ -- Cara Therapeutics, Inc. today announced positive results from a Phase II study for the treatment of acute post-operative pain with its novel, peptide-based, peripherally-acting kappa opioid agonist, CR845. The study successfully met its primary endpoint which measured the effect of CR845 treatment on reducing the amount of rescue opioid analgesics used in the 24 hour period post-surgery, as well as secondary endpoints which...

SAN FRANCISCO, June 7, 2012 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that the U.S. Food and Drug Administration (FDA) has designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain. NKTR-181 is a novel mu-opioid agonist molecule, which is designed to have a slow rate of entry into the brain to reduce the attractiveness of the molecule as a target of abuse and to reduce its CNS-mediated side effects. NKTR-181...

(Ivanhoe Newswire) – Acetaminophen, a widely available over-the-counter medication, can cause liver toxicity in children if doses are exceeded. It is the most common single agent responsible for a life-threatening event, longer-term illness or death. “Acetaminophen overdose is a major cause of acute liver failure and is the most common identifiable cause of acute liver failure in children,” Dr. Rod Lim of the Department of Pediatrics at the Children’s Hospital in London was as...

DUBLIN, June 5, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the company will make a presentation at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 8:00 a.m. EST/ 1:00 p.m. GMT. Bruce Cozadd, Chairman and Chief Executive Officer, will provide a business update. A live webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com....

Connie K. Ho for redOrbit.com Panic. Fear. These are thoughts that run through a parent’s mind when they find out their child is hurt or injured. It can be even more alarming if the situation is a medical emergency. Some medical-related incidences can be avoided, such as accidental medication overdoses with drugs like acetaminophen. An article published in the Canadian Medical Association Journal (CMAJ) stated that acetaminophen, a popular over-the-counter medicine, can lead to liver...

STAMFORD, Conn., June 4, 2012 /PRNewswire/ -- Purdue Pharma L.P. will present data evaluating physician understanding of the Risk Evaluation and Mitigation Strategy (or REMS) for Butrans® (buprenorphine) Transdermal System CIII at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting. The data includes results from a post-test evaluation of prescribers who completed Butrans REMS training between December 2010 and February...

Penn researcher calls for expansion of programs to identify potential drug abusers and protect pain patients Individual use of prescription opioids has increased four-fold since the mid-1990s, in part due to increased awareness of pain control for chronic conditions such as low back pain and fibromyalgia and a Joint Commission mandate that hospitals assess patients' pain as a "vital sign" along with their blood pressure and temperature. During the same timeframe, however, the number of...